<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03591133</url>
  </required_header>
  <id_info>
    <org_study_id>TS143-01-01</org_study_id>
    <nct_id>NCT03591133</nct_id>
  </id_info>
  <brief_title>Clinical Study of TS-143 in Healthy Adult Male Subjects (Single-Dose Administration)</brief_title>
  <official_title>Phase I Clinical Study of TS-143 in Healthy Adult Male Subjects (Single-Dose Administration)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taisho Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taisho Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the safety, pharmacokinetics and pharmacodynamics when administering a single
      dose of TS-143 to Japanese healthy adult males using a placebo-controlled, double-blind,
      dose-ascending study, in addition to the effects of meals.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 24, 2015</start_date>
  <completion_date type="Actual">April 14, 2016</completion_date>
  <primary_completion_date type="Actual">April 14, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>8 days</time_frame>
    <description>To evaluate the safety of TS-143 given single administration in healthy volunteers by incidence of adverse events which include abnormal electrocardiograms, vital signs, and clinical laboratory parameters.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentrations of unchanged form (ng/mL)</measure>
    <time_frame>72 hours</time_frame>
    <description>The descriptive statistics (e.g., number of subjects, arithmetic mean, standard deviation) were calculated by dose group and evaluation timing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary excretions of unchanged form (ng/mL)</measure>
    <time_frame>72 hours</time_frame>
    <description>The descriptive statistics (e.g., number of subjects, arithmetic mean, standard deviation) for the total urinary excretion (amount and fraction) were summarized by dose group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum erythropoietin (EPO) concentration</measure>
    <time_frame>72 hours</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Step1:3㎎ QD</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Drug: TS-143 3mg Drug: Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Step2:6㎎ QD</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Drug: TS-143 6mg Drug: Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Step3-1:11㎎ QD</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Drug: TS-143 11mg Drug: Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Step3-2:11㎎ QD（Fed)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Drug: TS-143 11mg Drug: Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Step4:20㎎ QD</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Drug: TS-143 20mg Drug: Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Step5:36㎎ QD</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Drug: TS-143 36mg Drug: Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TS-143</intervention_name>
    <arm_group_label>Step1:3㎎ QD</arm_group_label>
    <arm_group_label>Step2:6㎎ QD</arm_group_label>
    <arm_group_label>Step3-1:11㎎ QD</arm_group_label>
    <arm_group_label>Step3-2:11㎎ QD（Fed)</arm_group_label>
    <arm_group_label>Step4:20㎎ QD</arm_group_label>
    <arm_group_label>Step5:36㎎ QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Step1:3㎎ QD</arm_group_label>
    <arm_group_label>Step2:6㎎ QD</arm_group_label>
    <arm_group_label>Step3-1:11㎎ QD</arm_group_label>
    <arm_group_label>Step3-2:11㎎ QD（Fed)</arm_group_label>
    <arm_group_label>Step4:20㎎ QD</arm_group_label>
    <arm_group_label>Step5:36㎎ QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects with a body-mass index (BMI) of 18.5 to less than 25.0 at the time of the
             screening tests

          2. Subjects judged by the principal investigator or a subinvestigator to be appropriate
             for participation in the study based on the results of the screening tests and the
             tests conducted prior to the investigational drug treatment

        Exclusion Criteria:

          1. Subjects who meet any of the following criteria in the screening tests or the tests
             conducted on Day -1 and prior to the investigational drug treatment

               -  Red blood cell count: ≥ 535 × 10^4 /μL

               -  Hemoglobin: ≥ 16.2 g/dL

               -  Hematocrit: ≥ 47.5%

               -  Reticulocyte ratio: Outside of the reference value range

          2. Subjects who meet any of the following criteria in the screening tests

               -  Serum EPO concentration: Outside of the reference value range

               -  Ferritin: 30 ng/mL or less, or ≥ 262 ng/mL

          3. Subjects who meet any of the following criteria in the vital signs in the screening
             tests and the tests conducted prior to the investigational drug treatment

               -  Blood pressure: Systolic blood pressure ≥ 140 mmHg, or diastolic blood pressure ≥
                  90 mmHg or more

               -  Pulse rate: &lt; 40 bpm, or ≥ 100 bpm

               -  Body temperature: ≥ 37.5°C
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shigeru Okuyama</last_name>
    <role>Study Director</role>
    <affiliation>Taisho Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Taisho Pharmaceutical Co., Ltd selected site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <results_reference>
    <citation>Shinfuku A, Shimazaki T, Fujiwara M, Sato F, Watase H, Numazaki T, Kawakita Y, Mutoh M, Yamasaki H, Takayama N, Kato S, Sugimoto T, Maruyama J. Novel Compound Induces Erythropoietin Secretion through Liver Effects in Chronic Kidney Disease Patients and Healthy Volunteers. Am J Nephrol. 2018;48(3):157-164. doi: 10.1159/000492181. Epub 2018 Sep 3.</citation>
    <PMID>30176654</PMID>
  </results_reference>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>April 18, 2018</study_first_submitted>
  <study_first_submitted_qc>July 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2018</study_first_posted>
  <last_update_submitted>December 2, 2019</last_update_submitted>
  <last_update_submitted_qc>December 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

